중증 근무력증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Myasthenia Gravis Treatment Market size is expected to reach USD 5.05 Billion in 2034 from USD 2.74 Billion (2025) growing at a CAGR of 7.04% during 2026-2034.

The Myasthenia Gravis Treatment Market is experiencing significant growth as awareness and diagnosis of this autoimmune neuromuscular disorder increase. Myasthenia gravis is characterized by weakness and rapid fatigue of voluntary muscles, leading to challenges in daily activities. The rising prevalence of myasthenia gravis, coupled with advancements in treatment options, is driving the demand for effective therapies. As healthcare providers seek to improve patient outcomes and quality of life, the market for myasthenia gravis treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the myasthenia gravis treatment market. Innovations in pharmacological therapies, including monoclonal antibodies and immunosuppressive agents, are enhancing the management of myasthenia gravis symptoms. Additionally, advancements in diagnostic tools and biomarkers are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the myasthenia gravis treatment market is likely to see increased adoption of novel therapies and improved management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the myasthenia gravis treatment market's growth trajectory. As patients and their families become more informed about the condition and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug class

• Intravenous immunoglobulin
• Monoclonal antibodies
• Others

By Age group

• Below 55 years
• Above 55 years

By Distribution channel

• Hospital pharmacies
• Retail pharmacies
• Online providers

COMPANIES PROFILED

• Kedrion, CSL Limited, F HoffmannLa Roche Ltd, Astellas Pharma Inc, Bausch Health Companies Inc, Novartis AG, AstraZeneca, Grifols, Octapharma AG, Zydus Lifesciences Limited

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Intravenous immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Age Group
• 5.2. Below 55 years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Above 55 years Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online providers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Age Group
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Age Group
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Age Group
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Age Group
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Age Group
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MYASTHENIA GRAVIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Kedrion
  • 9.2.2 CSL Limited
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Astellas Pharma Inc
  • 9.2.5 Bausch Health Companies Inc
  • 9.2.6 Novartis AG
  • 9.2.7 AstraZeneca
  • 9.2.8 Grifols
  • 9.2.9 Octapharma AG
  • 9.2.10 Zydus Lifesciences Limited